Natalia Gonzalez, MD
Neurology · Durham, NCNPI 1023436177
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.9%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. UCB Biosciences Inc. accounts for 100.0% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $87,762 and has fallen 99.9% since, to $63 in 2025. Among neurology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 7 payments — averaging $31,395 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB Biosciences Inc.$220K
- Mallinckrodt Hospital Products Inc.$28
- Catalyst Pharmaceuticals, Inc.$18
- Acadia Pharmaceuticals Inc$16
Across 1 payment — averaging $22,825 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$23K
What the payments were for
- Consulting fees$131,64360%
- Speaking & faculty fees$88,06240%
- Food & beverage$630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB Biosciences Inc. | 4 | $219,706 |
| Mallinckrodt Hospital Products Inc. | 1 | $28 |
| Catalyst Pharmaceuticals, Inc. | 1 | $18 |
| Acadia Pharmaceuticals Inc | 1 | $16 |
How this compares
$219,768 in reported general payments places this provider in the 95th percentile of 566 neurology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EvrysdiRisdiplam | 21 | $552,402 |
| SkyclarysOmaveloxolone | 12 | $384,944 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 20 | $30,929 |
| Mycophenolate Mofetil | 52 | $16,082 |
| Pyridostigmine Bromide | 40 | $5,419 |
| Azathioprine | 28 | $1,971 |
| Gabapentin | 30 | $1,110 |
| Baclofen | 23 | $712 |
| Clonazepam | 67 | $621 |
| Prednisone | 54 | $482 |
| Levetiracetam | 12 | $210 |
| Lorazepam | 14 | $118 |
Paid to pharmacies, not to this prescriber.
Other neurology in Durham
- Kevin KahnDurham$587K
- Mark SkeenDurham$562K
- Alan FinkelDurham$284K
- Karissa GableDurham$203K
- Aatif HusainDurham$146K
- Jeffrey GuptillDurham$102K
- Nicole GillDurham$92K
- Rodney RadtkeDurham$69K
- Donald SandersDurham$64K
- Steve KirkDurham$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.